aTyr Pharma, Inc. (LIFE)
| Market Cap | 78.84M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -38.77M |
| Shares Out | 28.06M |
| EPS (ttm) | -1.72 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 89,277 |
| Open | 2.87 |
| Previous Close | 2.87 |
| Day's Range | 2.78 - 3.01 |
| 52-Week Range | 2.60 - 13.10 |
| Beta | 1.57 |
| Analysts | Buy |
| Price Target | 17.51 (+523.1%) |
| Earnings Date | Aug 9, 2022 |
About LIFE
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal ... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for LIFE stock is "Buy." The 12-month stock price forecast is 17.51, which is an increase of 523.13% from the latest price.
News
aTyr Pharma Announces FGFR4 as Receptor Target for AARS tRNA Synthetase Fragment
Poster to be presented at the Keystone Symposia on Tissue Fibrosis and Repair.
aTyr Pharma to Present Findings from its tRNA Synthetase Platform at the International 28th tRNA Conference
Conference hosted by The Ohio State University's Center for RNA Biology to showcase latest advancements in tRNA biology Conference hosted by The Ohio State University's Center for RNA Biology to showcas...
aTyr Pharma to Present at the 2022 Jefferies Healthcare Conference
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines from its proprietary tRNA synthe...
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on its proprietary tRNA sy...
Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates
Atyr Pharma (LIFE) delivered earnings and revenue surprises of -29.41% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
aTyr Pharma Announces First Quarter 2022 Results and Provides Corporate Update
Company to present clinical data for efzofitimod (ATYR1923) in pulmonary sarcoidosis at upcoming American Thoracic Society International Conference in May.
aTyr Pharma to Webcast Conference Call Reporting First Quarter 2022 Financial Results
Management to host conference call and webcast on May 9th at 5:00 pm EDT / 2:00 pm PDT Management to host conference call and webcast on May 9th at 5:00 pm EDT / 2:00 pm PDT
aTyr Pharma (LIFE) Up on Orphan Drug Status for Efzofitimod
The FDA bestows an Orphan Drug status to aTyr Pharma's (LIFE) lead candidate, efzofitimod, for the treatment of systemic sclerosis. Shares rise.
aTyr Pharma Announces FDA Orphan Drug Designation for Efzofitimod (ATYR1923) for Treatment of Systemic Sclerosis
Second U.S. orphan drug designation for efzofitimod clinical program Second U.S. orphan drug designation for efzofitimod clinical program
aTyr Pharma Presents Preclinical Research Characterizing Effects of ATYR2810 in Highly Aggressive Tumor Subtypes at t...
Findings suggest that ATYR2810 reduces metastasis and enhances chemosensitivity by downregulating key genes linked to these processes. Findings suggest that ATYR2810 reduces metastasis and enhances chem...
Does Atyr Pharma (LIFE) Have the Potential to Rally 236% as Wall Street Analysts Expect?
The consensus price target hints at a 235.8% upside potential for Atyr Pharma (LIFE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estima...
aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International C...
Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate safety and dose dependent trends of improvement compared to placebo for key efficacy endpoints.
Can Atyr Pharma (LIFE) Climb 266% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 265.6% upside potential for Atyr Pharma (LIFE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estima...
Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know
Atyr Pharma (LIFE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
aTyr Pharma Announces Fourth Quarter and Full Year 2021 Results and Provides Corporate Update
FDA End-of-Phase 2 meeting provides development pathway for efzofitimod (ATYR1923) in pulmonary sarcoidosis; planned registrational study to initiate in the third quarter of 2022.
aTyr Pharma Announces Positive End-of-Phase 2 Meeting with FDA on Efzofitimod for the Treatment of Pulmonary Sarcoidosis
Regulatory path forward supports company's intention to initiate a planned registrational study in the third quarter of 2022. Regulatory path forward supports company's intention to initiate a planned r...
aTyr Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathw...
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2021 Financial Results
Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDT Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDT
aTyr Pharma to Participate in Panel at National Institutes of Health Rare Disease Day®
Panel to take place on Monday, February 28, 2022, at 2:55pm EST / 11:55am PST Panel to take place on Monday, February 28, 2022, at 2:55pm EST / 11:55am PST
aTyr Pharma to Present at BIO CEO & Investor Conference
SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathwa...
aTyr Pharma Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonprop...
Efzofitimod expected to enter into a registrational trial for pulmonary sarcoidosis in 2022 Efzofitimod expected to enter into a registrational trial for pulmonary sarcoidosis in 2022
aTyr Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathwa...
aTyr Pharma Appoints Danielle Campbell as Vice President of Human Resources
SAN DIEGO, Dec. 24, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathwa...
aTyr Pharma to Present at Antibody Engineering & Therapeutics Conference
Novel engineering approach accelerates generation of new antibody candidates from tRNA synthetase platform. Novel engineering approach accelerates generation of new antibody candidates from tRNA synthet...
DEVITA Global Joins Hands With Bodi Insurance Group, Mongolia's Premier Insurance Provider, to Advance a Decentralize...
SEOUL, South Korea--(BUSINESS WIRE)---- $LIFE #DEVITA--DEVITA Global (“DEVITA”) together with the Bodi Insurance Group (“Bodi Insurance”) have agreed on a cooperation partnership for the joint developme...